W. Morris

发表

Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study.

K Otto, M Schmuland, W J Morris, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Limited‐stage diffuse large B‐cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy

R. Gascoyne, L. Sehn, J. Connors, 2012, Cancer.

A pilot study of a method of estimating the number of functional eccrine sweat glands in irradiated human skin.

W. J. Morris, S. Dische, G. Mott, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias.

Scott Tyldesley, Tom Pickles, W James Morris, 2003, International journal of radiation oncology, biology, physics.

Four-week arc radiotherapy for B2-C prostate cancer: the need for prospective evaluation of short fractionation schemes.

W. J. Morris, T. Pickles, P. Graham, 1997, Australasian radiology.

Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?

W. J. Morris, I. Spadinger, M. Keyes, 2010, International journal of radiation oncology, biology, physics.

Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.

W. J. Morris, M. Keyes, T. Pickles, 2010, International journal of radiation oncology, biology, physics.

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance

W. J. Morris, G. Duncan, S. Tyldesley, 2017, International journal of radiation oncology, biology, physics.

Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.

W. J. Morris, I. Spadinger, M. Keyes, 2014, International journal of radiation oncology, biology, physics.

Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.

W. J. Morris, M. Keyes, H. Pai, 2013, Brachytherapy.

Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Howard Pai, Ingrid Spadinger, Stacy Miller, 2009, International journal of radiation oncology, biology, physics.

Predictive factors of urinary retention following prostate brachytherapy.

W. J. Morris, I. Spadinger, M. Keyes, 2002, International journal of radiation oncology, biology, physics.

Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer

Howard Pai, Ingrid Spadinger, Scott Tyldesley, 2013, Cancer.

Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients.

Howard Pai, Ingrid Spadinger, Ross Halperin, 2012, Brachytherapy.

Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.

W. J. Morris, P. Warde, M. Brundage, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.

W. J. Morris, I. Spadinger, M. Keyes, 2009, Urology.

Canadian prostate brachytherapy in 2012.

Nawaid Usmani, Tom Pickles, Mira Keyes, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Deformable prostate registration from MR and TRUS images using surface error driven FEM models

Orcun Goksel, Septimiu E. Salcudean, William J. Morris, 2012, Medical Imaging.

Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.

Septimiu Salcudean, Ingrid Spadinger, W James Morris, 2012, Medical physics.

An Updated Analysis of the Survival Endpoints of ASCENDE-RT.

W. J. Morris, M. Keyes, G. Duncan, 2022, International journal of radiation oncology, biology, physics.

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

W. J. Morris, M. Keyes, G. Duncan, 2017, International journal of radiation oncology, biology, physics.

Treatment options for localized prostate cancer.

Nawaid Usmani, Mira Keyes, W James Morris, 2013, Canadian family physician Medecin de famille canadien.

Canadian consensus definition of prostate cancer risk stratification

W. J. Morris, M. Keyes, É. Vigneault, 2013 .

Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?

W. J. Morris, S. Tyldesley, T. Pickles, 2012, BJU international.

Clinical impact of second pathology opinion: a longitudinal study of central genitourinary pathology review before prostate brachytherapy.

Carys W Thomas, C. McGahan, T. Thomson, 2007, Brachytherapy.

Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.

W. J. Morris, M. Keyes, T. Pickles, 2018, Brachytherapy.

Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy.

W. J. Morris, I. Spadinger, M. Keyes, 2009, Brachytherapy.

Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants.

K. Otto, W. J. Morris, I. Spadinger, 2002, International journal of radiation oncology, biology, physics.

Real-Time Dosimetry for Prostate Brachytherapy Using TRUS and Fluoroscopy

Septimiu E. Salcudean, William J. Morris, Daniel French, 2004, MICCAI.

High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.

W. J. Morris, M. Keyes, T. Pickles, 2017, Brachytherapy.

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

W. J. Morris, M. Keyes, S. Tyldesley, 2014, International journal of radiation oncology, biology, physics.

Automatic dual air kerma strength treatment planning for focal low-dose-rate prostate brachytherapy boost using dosimetric and geometric constraints

Michael D. Peacock, W. J. Morris, I. Spadinger, 2020, 2010.12617.

Prostate brachytherapy postimplant dosimetry: a comparison of suture-embedded and loose seed implants.

Michelle Hilts, Ingrid Spadinger, William J Morris, 2006, Brachytherapy.

Semiautomatic segmentation for prostate brachytherapy: dosimetric evaluation.

S. Salcudean, W. J. Morris, I. Spadinger, 2013, Brachytherapy.

Prostate implant reconstruction from C-arm images with motion-compensated tomosynthesis.

Gabor Fichtinger, Ehsan Dehghan, Mehdi Moradi, 2011, Medical physics.

Brachytherapy seed reconstruction with joint-encoded C-arm single-axis rotation and motion compensation

Gabor Fichtinger, Ehsan Dehghan, Mehdi Moradi, 2011, Medical Image Anal..

Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer

Nicholas Bruchovsky, W James Morris, M. Gleave, 2006, Cancer.

Registration of trans-perineal template mapping biopsy cores to volumetric ultrasound

Tajwar Abrar Aleef, S. Salcudean, W. J. Morris, 2022, International Journal of Computer Assisted Radiology and Surgery.

Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?

Joseph Bucci, Michael McKenzie, Tom Pickles, 2006, International journal of radiation oncology, biology, physics.

17 Rectal Toxicity After I 125 Permanent

W. J. Morris, M. Keyes, V. Moravan, 2005 .

Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?

W. J. Morris, A. Macdonald, M. Keyes, 2005, International journal of radiation oncology, biology, physics.

Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma

W. J. Morris, M. Keyes, G. Duncan, 2002, Cancer.

ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

W. J. Morris, G. Duncan, J. Hamm, 2017, International Journal of Radiation Oncology, Biology, Physics.

A biochemical definition of cure after brachytherapy for prostate cancer.

G. Merrick, W. J. Morris, J. Ciezki, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.

C. MacAulay, W. J. Morris, M. Keyes, 2013, International journal of radiation oncology, biology, physics.

Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room?

W. J. Morris, I. Spadinger, R. Halperin, 2010, Brachytherapy.

Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.

W. J. Morris, I. Spadinger, M. Keyes, 2009, International journal of radiation oncology, biology, physics.

Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive (125)I monotherapy patients.

Ingrid Spadinger, Michael McKenzie, Tom Pickles, 2014, Brachytherapy.

A robotic needle guide for prostate brachytherapy

Septimiu E. Salcudean, William J. Morris, Ingrid Spadinger, 2008, 2008 IEEE International Conference on Robotics and Automation.

Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study

Silvia D. Chang, Michael D. Peacock, S. Salcudean, 2017, Journal of contemporary brachytherapy.

3D Needle-Tissue Interaction Simulation for Prostate Brachytherapy

Orcun Goksel, Robert Rohling, Septimiu E. Salcudean, 2005, MICCAI.

A Multi-Atlas-Based Segmentation Framework for Prostate Brachytherapy

Purang Abolmaesumi, William J. Morris, Saman Nouranian, 2015, IEEE Transactions on Medical Imaging.

An Automatic Multi-atlas Segmentation of the Prostate in Transrectal Ultrasound Images Using Pairwise Atlas Shape Similarity

Purang Abolmaesumi, Septimiu E. Salcudean, William J. Morris, 2013, MICCAI.

Prostate brachytherapy postimplant dosimetry: automatic plan reconstruction of stranded implants.

I Spadinger, N Chng, W J Morris, 2010, Medical physics.

Prostate Brachytherapy Training With Simulated Ultrasound and Fluoroscopy Images

Orcun Goksel, Septimiu E. Salcudean, William J. Morris, 2013, IEEE Transactions on Biomedical Engineering.

When to treat prostate cancer patients based on their PSA dynamics

William J. Morris, Martin L. Puterman, Scott Tyldesley, 2012 .

Viscoelasticity Modeling of the Prostate Region Using Vibro-elastography

Septimiu E. Salcudean, William J. Morris, Simon Bachmann, 2006, MICCAI.

PSA relapse definitions--the Vancouver Rules show superior predictive power.

W. J. Morris, G. Duncan, T. Pickles, 1999, International journal of radiation oncology, biology, physics.

Urethral and periurethral dosimetry in prostate brachytherapy: is there a convenient surrogate?

W. J. Morris, I. Spadinger, M. Keyes, 2002, International journal of radiation oncology, biology, physics.

Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.

W. J. Morris, M. Keyes, S. Tyldesley, 2015, International journal of radiation oncology, biology, physics.

Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.

W. J. Morris, I. Spadinger, A. Kruk, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy.

Tom Pickles, Mira Keyes, W James Morris, 2004, International journal of radiation oncology, biology, physics.

Low-Dose-Rate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavourable Risk Prostate Cancer: The Results of the ASCENDE-RT* Randomized Control Trial

W. J. Morris, M. Keyes, G. Duncan, 2015 .

Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants.

Nawaid Usmani, Ingrid Spadinger, Nick Chng, 2011, Brachytherapy.

Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%.

W. J. Morris, S. Tyldesley, M. Joffres, 2012, International journal of radiation oncology, biology, physics.

Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

Howard Pai, William James Morris, Ingrid Spadinger, 2013, Brachytherapy.

Multi-atlas-based automatic 3D segmentation for prostate brachytherapy in transrectal ultrasound images

Purang Abolmaesumi, Septimiu E. Salcudean, William J. Morris, 2013, Medical Imaging.

Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.

W. J. Morris, M. Keyes, S. Tyldesley, 2018, International journal of radiation oncology, biology, physics.

Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer.

Michael W Kattan, Tom Pickles, Mira Keyes, 2011, Brachytherapy.

ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.

W. J. Morris, G. Duncan, S. Tyldesley, 2015 .

The role of the vitreous in the intraocular pressure rise after neodymium-YAG laser capsulotomy.

E. Balazs, W. J. Morris, S. Trokel, 1985, A M A Archives of Ophthalmology.